ReNeuron Holdings plc (the “Company”)
Result of EGM
The Company announces that at today’s extraordinary general meeting the ordinary resolution proposed at the meeting was passed. The resolution, set out in the Offer Document published on 8 April 2003, permits Dr Martin Edwards, Dr John Sinden and Dr Helen Hodges to participate in a share exchange in connection with the offer for the Company by St. James’s MGP Limited.
ReNeuron scientists (1) today presented recent data on ReNcell, the Company’s human neural stem cell lines for use in drug discovery. ReNeuron is promoting ReNcell to pharmaceutical companies involved in CNS drug discovery and to academic groups involved in stem cell research.
ReNeuron has noted yesterday’s vote by MEPs against the use of embryonic stem cells (ESC’s) in research and for special rules for the use of human foetal tissue. Both votes were taken on amendments tabled to the Human Tissue and Cells Safety Directive.
DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3 OF THE CITY CODE ON TAKEOVERS AND MERGERS
Date of dealing – 09/04/03
Dealing in RENEURON HOLDINGS
In connection with the Offer, being made by KPMG Corporate Finance on behalf of St. James’s MGP Limited (“St. James’s”), the board of St James’s announces that the Offer Document and related Form of Acceptance are being posted today to ReNeuron Shareholders and, for information only, to participants in the ReNeuron Share Option Schemes.
RECOMMENDED CASH OFFER
at 10 pence per share
by
KPMG Corporate Finance
on behalf of
St. James’s MGP Limited (“St. James’s”)
for
ReNeuron Holdings plc (“ReNeuron”)
Summary
The board of St. James’s and the Independent Directors of ReNeuron are pleased to announce that they have reached agreement on the terms of a recommended cash offer, to be made by KPMG Corporate Finance on behalf of St. James’s, to acquire the entire issued share capital of ReNeuron not already owned or contracted to be acquired by St. James’s. St. James’s is a newly incorporated company formed in order to implement the Offer and is owned and controlled by the Merlin Consortium.
Lodge with Company Announcements Office and the Panel. Use a separate form for each class of securities in which dealings have been made.
The Board of ReNeuron has noted the recent press speculation concerning the possibility of a sale of the Company. The Board confirms that it has received an approach and is in discussions which may or may not lead to an offer for the Company.
A further announcement will be made when appropriate.
Anna Rainbow
Smithfield Financial
020 7360 4900 or 07850 138260
Guildford, UK, 14 May 2009: ReNeuron Group plc (LSE: RENE.L) today provides a regulatory update regarding its ReN001 stem cell therapy for stroke. In January of this year, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) granted regulatory approval for a Phase I clinical trial with ReN001 in disabled stroke patients, to be undertaken in Scotland at Glasgow Southern General Hospital. The decision was ratified by the Commission on Human Medicines, with the support of its Clinical Trials Expert Advisory Group which was also involved in reviewing the application.
